Clinical trial
A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline
NCT00143299 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00143299 |
|---|---|
| Title | A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline |
| Official title | A 52-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety of Varenicline Tartrate ( CP-526,555) for Smoking Cessation |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Smoking Cessation |
| Intervention type | Drug |
| Interventions | varenicline (CP-526, 555) |
| Enrollment | 375 |
| Start date | Oct 1, 2003 |
| Completion | Mar 1, 2005 |
| First posted | Sep 2, 2005 |
| Last update posted | Jun 4, 2007 |
| Countries | Australia, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: